Work

Virologic Outcomes After Long-Acting Antiretroviral Therapy Initiation With and Without Viremia in 2 Large US Clinic Cohorts

Year: 2026

Type: article

Study design: Observational Study

Abstract: Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.

Source: Clinical Infectious Diseases

DOI: 10.1093/cid/ciag392

Authors: Matthew A Spinelli, Megan J Heise, David V Glidden, Janet Grochowski, Jon Oskarsson, Larisa Niles-Carnes, Eudiah Ochieng, Meredith Lora, Amalia Aldredge, Nathanael Gistand, Chesa Cox, Jonathan A Colasanti, Monica Gandhi, Lauren F Collins

Institutions: University of California, San Francisco, Grady Memorial Hospital, Emory University

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,763

Funders: National Institutes of Health, National Institute of Allergy and Infectious Diseases

Awards: G2208902113, G7659283644

OpenAlex ID: W7166547721

FWCI: 19.32

Cites: 10

Cited by: 4

Related to: